X

Trial Profile

A phase II multicenter, open-label study of YM155 in refractory diffuse large B-cell lymphoma (DLBCL) subjects

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sepantronium bromide (Primary)
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Sponsors Astellas Pharma

Most Recent Events

30 Sep 2021 This trial has been completed in France (End Date: 23 Apr 2009), according to European Clinical Trials Database record.
12 May 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
12 May 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com